OnEMI Technology Solutions Limited moves to reshape its capital structure

The preferential issue comprises 34 proposed non-promoter allottees, receiving up to 26,493,882 shares at Rs 314.11 per share, for an aggregate Rs 832.19 crore. The allotment remains subject to shareholder and regulatory approvals ^{[1] [2]}.

Proposed allottees

Pricing comparison

• Versus book value: The latest available financial snapshot does not report a numerical book value per share; the Book Value field is blank ^[4]. Therefore, the issue price-to-book ratio and the premium or discount to book value cannot be calculated reliably.
• Versus the previous IPO: The immediately preceding public fundraise was priced at Rs 171 per share and was reported to imply a Rs 3,062 crore post-money valuation at the upper end of the IPO price band ^[5]. The preferential issue price of Rs 314.11 is Rs 143.11 higher, or 83.69% above the IPO price, calculated from the two disclosed prices ^{[1] [5]}.
• Valuation interpretation: The Rs 3,062 crore figure is the prior IPO’s reported post-money valuation. A precise current post-money valuation cannot be stated without an authoritative current post-issue share count; the preferential issue’s 26,493,882 new shares create dilution, so applying the 83.69% price increase directly to Rs 3,062 crore would be misleading ^{[1] [5]}.

Read-through: The issue is clearly priced well above the IPO’s per-share level, but the absence of a reported current book value and authoritative post-issue equity base prevents a clean price-to-book or current post-money valuation comparison.

The Rs 832 crore infusion should materially strengthen Si Creva’s Tier-1 capital base, but the post-infusion Tier-1 CAR cannot be calculated from the disclosed information. The uplift will depend on how much of the capital is retained as regulatory capital versus deployed into loans, and on the corresponding increase in risk-weighted assets. Si Creva’s reported capital adequacy was 30.01% at end-1HFY26, but the disclosed figure is not identified as a post-infusion Tier-1 CAR. ^[6]

Deployment plan

\*Derived from approximately Rs 832 crore multiplied by the disclosed 75%/25% allocation; amounts are approximate. ^[2]

Key distinction: management has not disclosed a further split within the Rs 624 crore earmarked for Si Creva between incremental loan-book funding and technology infrastructure. The stated plan groups both objectives together: lending-scale expansion as well as technology and digital investment. ^[2]

CAR implication: initially, the equity infusion should provide greater capital headroom for loan growth and support the company’s objective of pursuing credit-rating upgrades. However, as the funds are converted into loans, risk-weighted assets will also rise; therefore, the eventual Tier-1 CAR benefit will be lower than the simple increase in capital and cannot be expressed as a precise percentage-point improvement without the post-infusion capital base, risk-weighted assets, and regulatory treatment of the subsidiary infusion. The preferential issue itself remained subject to shareholder and regulatory approvals when announced. ^[2]

Verdict: The Rs 832 Crores OnEMI preferential issue is a primary-capital raise, not a secondary sell-down. On the disclosed terms, all proceeds are intended to strengthen the company and its lending subsidiary; existing shareholders will face share-count dilution, but the exact percentage cannot be calculated without the pre-issue share count and post-issue cap table.

OnEMI’s allocation is balance-sheet accretive in purpose. Approximately Rs 624 Crores, derived as 75% of the Rs 832 Crores issue, is to be infused into wholly owned Si Creva Capital Services for lending growth, technology and product expansion. The remaining approximately Rs 208 Crores, derived as 25%, is for general corporate purposes ^[2]. This is materially different from an OFS, where the issuer receives no capital.

The closest contrasting example is ARCIL. ARCIL’s Rs 733 Crores IPO was entirely an offer for sale by promoters and existing shareholders; the company received no proceeds ^[8]. Economically, that transaction changes ownership and public float but does not recapitalise the operating entity. It is therefore a capital-markets liquidity event rather than a balance-sheet funding event.

The named peer set is not fully comparable:

• ARCIL: Clear 100% secondary/OFS structure, as above.
• Centrum Capital: Reported plans included an equity fundraise and approval of share warrants, but the cited disclosure does not provide an executed primary-versus-secondary split ^[11].
• Colab Platforms, Algoquant Fintech and Gyftr: No primary-versus-secondary transaction terms are reported for a comparable raise; they cannot be ranked on this dilution axis.
• Jio Credit: Although larger and not a like-for-like size comparison, its BofA transaction also illustrates a primary strategic-capital model: preferential equity and warrants were used to build BofA’s stake, rather than a reported sale by existing holders ^[9].

Analytical implication: OnEMI’s structure maximises balance-sheet benefit but also creates genuine ownership and future EPS dilution because new shares are issued. ARCIL’s OFS avoided share-count dilution and added no capital to the business, while shifting liquidity to existing investors. The key unresolved variable for OnEMI is therefore not the primary-versus-secondary mix—it is the post-issue ownership percentage, which requires the pre-issue equity base and final allotment details. The preferential issue also remained subject to shareholder and regulatory approvals when announced ^[2].